$CSTL News

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

Castle Biosciences, Inc. Q2 2026 Earnings Call Summary

Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ...

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

Castle Biosciences Q2 Earnings Call Highlights

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences (NASDAQ:CSTL) Surges After Smashing Q2 Estimates and Raising Guidance

Castle Biosciences Reports Second Quarter 2026 Results

Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est

Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down

DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

Castle Biosciences Announces Published Study In 'Dermatology And Therapy' Showing DecisionDx-Melanoma Test Outperforms MIA Nomogram In Predicting Sentinel Lymph Node Positivity Risk